New active ingredients with high prices: Innovations with system-disrupting potential?;Neue wirkstoffe mit hohen preisen: Innovationen mit systemsprengendem potenzial?

Pharmazie in Unserer Zeit

Volumn 37, Issue 5, 2008, Pages 416-422

  Pfannkuche, Matthias S ^a   Glaeske, Gerd ^b  

^a UNIVERSITY OF BREMEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; SORAFENIB; SUNITINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

DRUG COST; DRUG STRUCTURE; HUMAN; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; COST BENEFIT ANALYSIS; DRUG ANTAGONISM; ECONOMICS; NEOPLASM; RANDOMIZED CONTROLLED TRIAL;

COST-BENEFIT ANALYSIS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 55249108683     PISSN: 00483664     EISSN: 16151003     Source Type: Journal    
DOI: 10.1002/pauz.200800282     Document Type: Review

References (33)

1. Arteaga, C.L.: Selecting the right patient for tumor therapy. Nat. Med. 10 (2004), 577-578.
2. Bausch, J.: Teure Tyrosinkinasehemmer mit systemsprengender Wirkung. AVP 34 (2007), 94-96.
3. Bayer HealthCare Pharmaceuticals: Bayer and Onyx Provide Update on Phase III Trial of Nexavar® in Patients with Non-Small Cell Lung Cancer. www.bayer.com/en/News-Detail.aspx?id=10563 (letzter Zugriff: 19.02.2008).
4. Blanke, C.D., Rankin, C., Demetri, G.D., Ryan, C.W., von Mehren, M., Benjamin, R.S., et al.: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 26 (2007), 626-632.
5. Blanke, C.D., Demetri, G.D., von Mehren, M., Heinrich, M.C., Eisenberg, B., Fletcher, J.A., et al.: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26 (2007), 620-625.
6. Chu, T.F., Rupnick, M.A., Kerkela, R., Dallabrida, S.M., Zurakowski, D., Nguyen, L., et al.: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370 (2007), 2011-2019.
7. Dalziel, K., Round, A., Stein, K., Garside, R., Price, A.: Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technol Assess 8 (2004), 1-120.
8. Deutsches Institut für für Medizinische Dokumentation und Information (DIMDI): Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen. Amtliche Fassung des ATC-Index mit DDDAngaben für Deutschland im Jahre 2008. www.dimdi.de/dynamic/de/klassi/downloadcenter/atcddd/version2008/ atc-ddd-amtlich-2008.pdf (letzter Zugriff: 14.02.2008)
9. European Medicines Agency (EMEA): EPARs for authorised medicinal products for human use. www.emea.europa.eu/htms/human/epar/eparintro.htm (letzter Zugriff: 14.02.2008)
10. Giaccone, G., Rodriguez, J.A.: EGFR inhibitors: what have we learned from the treatment of lung cancer. Nat. Clin. Pract. Oncol. 2 (2005), 554-561.
11. Glaeske, G.: Warum sind einige Arzneimittel so teuer? - Die Preispolitik der Hersteller - "Totengräber unseres Systems" -. ZaeFQ (2008), in Druck.
12. Grimm, C.F., Blum, H.E., Geissler, M.: Tyrosine kinase inhibitors in tumor therapy - part 1. Molecular and genetic fundamentals. DMW 130 (2005), 1318-1322.
13. Grimm, C.F., Blum, H.E., Geissler, M.: Tyrosine kinase inhibitors in tumor therapy - part 2. Current position and perspectives. DMW 130 (2005), 1438-1442.
14. Henshall, C., Oortwijn, W., Stevens, A., Granados, A., Banta, D.: Priority setting for health technology assessment. Theoretical considerations and practical approaches. Priority setting Subgroup of the EUR-ASSESS Project. Int. J. Technol. Assess Health Care; 13 (1997), 144-185.
15. Hohenberger, P.: Therapie mit "small molecules". Der Onkologe 10 (2004), 38-45.
16. Ludwig, W.D.: Beispiele für Arzneimittel(des)information an speziellen Präparategruppen - "off-label-use" in der Onkologie. Vortrag im Rahmen der Jubiläumsveranstaltung aus Anlass des 40. Jahrgangs DER ARZNEIMITTELBRIEF. 2. September 2006, Berlin.
17. Mathur, A., Sangani, N., Zhao, K.: Genentech. http://pages.stern.nyu.edu/ ~iag/presentations/2006-2007/dna.pdf (letzter Zugriff: 14.02.2008).
18. National Institute for Health and Clinical Excellence (NICE): Technology Appraisal 70. Guidance on the use of imatinib for chronic myeloid leukaemia. www.nice.org.uk/nicemedia/pdf/TA70_Imatinib_fullguidance.pdf (letzter Zugriff: 14.02.2008).
19. National Institute for Health and Clinical Excellence (NICE): Technology Appraisal (in development). Lung cancer (non small cell) - erlotinib. www.nice.org.uk/guidance/index.jsp?action=byID&o=11714 (letzter Zugriff: 14.02.2008).
20. Rawlins, M.D., Culyer, A.J.: National Institute for Clinical Excellence and its value judgments. BMJ 329 (2004), 224-227.
21. Robert Koch-Institut (Hrsg): Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes. Robert Koch-Institut, Berlin (2006).
22. Sawicki, P.T., Bender, R., Selke, G.W., Klauber, J., Gutschmidt, S.: Assessment of the number of cardio- and cerebrovascular events due to rofecoxib (Vioxx) in Germany between 2001 and 2004. Med. Klin. 101 (2006), 191-197.
23. Schiffer, C.A.: BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N. Engl. J. Med. 357 (2007), 258-265.
24. Schöffski, O., Cremers, Y.: Pharmakoökonomie: Fluch oder Segen für die medizinische Versorgung. Pharm Unserer Zeit 36 (2007), 464-469.
25. Schwabe, U., Paffrath, D.: Arzneiverordnungsreport 2001. Springer, Berlin, Heidelberg (2001).
26. Schwabe, U., Paffrath, D.: Arzneiverordnungsreport 2002. Springer, Berlin, Heidelberg (2002).
27. Schwabe, U., Paffrath, D.: Arzneiverordnungsreport 2006. Springer, Berlin, Heidelberg (2006).
28. Schwabe, U., Paffrath, D.: Arzneiverordnungsreport 2007. Springer, Berlin, Heidelberg (2007).
29. Thatcher, N., Chang, A., Parikh, P., Pereira, J.R., Ciuleanu, T., Carroll, K., et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005), 1527-1537.
30. U.S. Food and Drug Administration (FDA): Center for Drug Evaluation and Research. FDA approved drug products. www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=(2008). Search.Search_Drug_Name (letzter Zugriff: 14.02.2008).
31. Wilson, J., Connock, M., Song, F., Yao, G., Fry-Smith, A., Raftery, J., et al.: Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol. Assess 9 (2005), 1-142.
32. WINAPO® Lauer Taxe: Lauer Fischer GmbH. Stand: 01.02.2008.
33. Zentner, A., Velasco-Garrido, M., Busse, R.: Methoden zur vergleichenden Bewertung pharmazeutischer Produkte. http://gripsdb.dimdi.de/de/hta/ hta_berichte/hta122_bericht_de.pdf (letzter Zugriff: 14.02.2008).